Analgesic effect of oxytocin and its effectiveness in acute pain management: A systematic review.

SemergenJun 10, 2026 (epub)
Clinical ResearchAnesthesiology

H El Mouaddib, J Nguidi, B Oukfi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the analgesic effects of oxytocin (OT) in acute pain management across various studies. It included ten studies published from 2014 to 2024, revealing that OT's effectiveness varied by pain context, with some studies showing pain reduction in experimental settings. The review highlights OT's potential as a pain modulator rather than a universal analgesic.

Key findings

  • Oxytocin's analgesic effects varied by acute pain context, with some studies showing significant pain reduction.
  • Routes of administration included intranasal (24-40 IU), intrathecal, intravenous, and subcutaneous.
  • Reported adverse effects were generally mild, indicating a favorable safety profile.

Why it matters

Understanding the role of oxytocin in acute pain management could provide clinicians with alternative strategies to reduce reliance on traditional analgesics, potentially improving patient outcomes and safety.

Source

PubMed · PMID 42269311

Published in Semergen. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Anesthesiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.